https://nedisertibinhibitor.co....m/impact-regarding-f
INTRODUCTION Endometrial cancer (EC) known prognostic facets aren't sufficient to anticipate either result or recurrence rate/site to research EC recurrence patterns according to ESMO-ESGO-ESTRO risk classes, might be good for an even more tailored adjuvant treatment and follow-up routine. PRACTICES 758 women clinically determined to have EC, and a 5-years followup, were enrolled these were divided into the ESMO-ESGO-ESTRO danger classes (reduced LR, intermediate IR, intermediate-high I-HR, a
Like
Comment
Share
